{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:44:29Z","timestamp":1773096269802,"version":"3.50.1"},"reference-count":57,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":2803,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57,<jats:italic>P<\/jats:italic>= 0.004) and at 6 months (RR = 2.78,<jats:italic>P<\/jats:italic>= 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy (<jats:italic>P<\/jats:italic>= 0.002) but not at 6 months (<jats:italic>P<\/jats:italic>= 0.37). There was no significant difference in positive (<jats:italic>P<\/jats:italic>= 0.28) or negative symptoms (<jats:italic>P<\/jats:italic>= 0.49) between the bupropion and the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.bp.109.066019","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T22:25:40Z","timestamp":1272666340000},"page":"346-353","source":"Crossref","is-referenced-by-count":66,"title":["Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis"],"prefix":"10.1192","volume":"196","author":[{"given":"Daniel Tai-yin","family":"Tsoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamta","family":"Porwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Claire","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000252446_ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000162802.54076.18"},{"key":"S0007125000252446_ref1","volume-title":"Policy Recommendations on Smoking Cessation and Treatment of Tobacco Dependence","year":"2003"},{"key":"S0007125000252446_ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0610-6"},{"key":"S0007125000252446_ref30","first-page":"226S","article-title":"Smoking cessation in schizophrenia: a double blind placebo controlled trial of bupropion SR added to cognitive behavioral therapy","volume":"55","author":"Evins","year":"2004","journal-title":"Biological Psychiatry"},{"key":"S0007125000252446_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00191-7"},{"key":"S0007125000252446_ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2006.tb00458.x"},{"key":"S0007125000252446_ref52","volume-title":"Choosing Health: Making Healthier Choices Easier.","year":"2004"},{"key":"S0007125000252446_ref49","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.3.212"},{"key":"S0007125000252446_ref45","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.183.6.534"},{"key":"S0007125000252446_ref44","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007013"},{"key":"S0007125000252446_ref46","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100803"},{"key":"S0007125000252446_ref40","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4.2528"},{"key":"S0007125000252446_ref39","doi-asserted-by":"publisher","DOI":"10.1080\/14622200110050510"},{"key":"S0007125000252446_ref36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0304"},{"key":"S0007125000252446_ref54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300861"},{"key":"S0007125000252446_ref38","first-page":"465","article-title":"A comparison of bupropion SR and placebo for smoking cessation","volume":"33","author":"Weiner","year":"2007","journal-title":"Schizophr Bull"},{"key":"S0007125000252446_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.02.007"},{"key":"S0007125000252446_ref53","doi-asserted-by":"publisher","DOI":"10.1080\/14622200701382033"},{"key":"S0007125000252446_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.016"},{"key":"S0007125000252446_ref57","doi-asserted-by":"publisher","DOI":"10.1136\/tc.2006.017657"},{"key":"S0007125000252446_ref29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0915"},{"key":"S0007125000252446_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.021"},{"key":"S0007125000252446_ref8","doi-asserted-by":"publisher","DOI":"10.1177\/070674379704200107"},{"key":"S0007125000252446_ref27","first-page":"s254","article-title":"A randomized, double-blind, placebo-controlled trial of sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia: neuropsychological predictors of treatment outcome","volume":"31","author":"George","year":"2006","journal-title":"Neuropsychopharmacol"},{"key":"S0007125000252446_ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"S0007125000252446_ref6","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"key":"S0007125000252446_ref48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.8.1334"},{"key":"S0007125000252446_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)80234-7"},{"key":"S0007125000252446_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(96)00302-2"},{"key":"S0007125000252446_ref26","volume-title":"Society for Research on Nicotine and Tobacco 10th Annual Meeting","author":"Sacco","year":"2004"},{"key":"S0007125000252446_ref4","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.156.11.1751","article-title":"Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland","volume":"156","author":"Kelly","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0007125000252446_ref31","volume-title":"Society for Research on Nicotine and Tobacco 9th Annual Meeting","author":"Evins","year":"2003"},{"key":"S0007125000252446_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0269881104047273"},{"key":"S0007125000252446_ref11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)37928-5","article-title":"Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine","volume":"288","author":"Fryer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"S0007125000252446_ref25","volume-title":"Society for Research on Nicotine and Tobacco 13th Annual Meeting.","author":"George","year":"2007"},{"key":"S0007125000252446_ref13","volume-title":"Smoking Reduction and Cessation for People with Schizophrenia: Guidelines for General Practitioners.","author":"Strasser","year":"2001"},{"key":"S0007125000252446_ref50","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.6.573"},{"key":"S0007125000252446_ref14","volume-title":"The ICD\u201310 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","year":"1992"},{"key":"S0007125000252446_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00161-3"},{"key":"S0007125000252446_ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00995.x"},{"key":"S0007125000252446_ref10","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v06n0403"},{"key":"S0007125000252446_ref9","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"1","author":"Hughes","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125000252446_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1445-7"},{"key":"S0007125000252446_ref34","volume-title":"Society for Research on Nicotine and Tobacco 9th Annual Meeting","author":"Evins","year":"2003"},{"key":"S0007125000252446_ref22","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0b013e3180ca86fa"},{"key":"S0007125000252446_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01339-2"},{"key":"S0007125000252446_ref24","first-page":"s101","article-title":"A placebo-controlled study of bupropion SR added to high dose nicotine replacement therapy for smoking cessation or reduction in schizophrenia","volume":"9","author":"Evins","year":"2007","journal-title":"Nicotine Tob Res"},{"key":"S0007125000252446_ref32","doi-asserted-by":"publisher","DOI":"10.1080\/14622200110073920"},{"key":"S0007125000252446_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.11.002"},{"key":"S0007125000252446_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.01.014"},{"key":"S0007125000252446_ref51","volume-title":"Smoking cessation Pharmacotherapy: An Update for Health Professionals","author":"Zwar","year":"2007"},{"key":"S0007125000252446_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.010"},{"key":"S0007125000252446_ref15","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM\u2013IV)","year":"1994"},{"key":"S0007125000252446_ref43","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000180737.85895.60"},{"key":"S0007125000252446_ref18","volume-title":"Treating Tobacco Use and Dependence: 2008 Update \u2013 Clinical Practice Guideline","author":"Fiore","year":"2008"},{"key":"S0007125000252446_ref35","first-page":"s187","article-title":"Bupropion versus placebo for smoking cessation in schizophrenia","volume":"66","author":"Vessicchio","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"S0007125000252446_ref21","first-page":"s103","article-title":"Predictors of smoking cessation in schizophrenia: analysis of data from three sequential controlled clinical trials","volume":"29","author":"George","year":"2004","journal-title":"Neuropsychopharmacol"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000252446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:45:56Z","timestamp":1740055556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000252446\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0007125000252446"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.109.066019","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}